(S)-1-boc-4-(2-cbz-氨基-2-甲氧基羰基乙基)哌啶 | 195877-54-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-1-boc-4-(2-cbz-氨基-2-甲氧基羰基乙基)哌啶
• 中文别名: (S)-4-(2-CBZ-氨基-2-甲酸甲酯烯丙基)-1-N-BOC-哌啶
• 英文名称: tert-butyl 4-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methoxy-3-oxopropyl]piperidine-1-carboxylate
• 英文别名: (S)-tert-Butyl 4-(2-(((benzyloxy)carbonyl)amino)-3-methoxy-3-oxopropyl)piperidine-1-carboxylate；tert-butyl 4-[(2S)-3-methoxy-3-oxo-2-(phenylmethoxycarbonylamino)propyl]piperidine-1-carboxylate
• CAS: 195877-54-4
• 化学式: C₂₂H₃₂N₂O₆
• 分子量: 420.506
• InChiKey: DETHWRBYCXAMSF-SFHVURJKSA-N

物化性质

• 沸点：
  546.3±35.0 °C(Predicted)
• 密度：
  1.151±0.06 g/cm3(Predicted)
• pKa：
  10.91±0.46 (Predicted,Most Acidic Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  30
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  94.2
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  (S)-1-boc-4-(2-cbz-氨基-2-甲氧基羰基乙基)哌啶 在 盐酸 、 二碳酸二叔丁酯 、 苄基三乙基氯化铵 、 二异丁基氢化铝 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 4-((S)-2-Benzyloxycarbonylamino-3-hydroxy-3-methoxycarbonyl-propyl)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Solution-phase and solid-phase synthesis of novel transition state inhibitors of coagulation enzymes incorporating a piperidinyl moiety

  摘要：

  2-Amino-3-piperidin-4-yl-propionic acid containing peptidomimetics are potent protease inhibitors when combined with an appropriate keto-thiazole or keto-carboxylic acid moiety. A novel P-1 residue in factor Xa and thrombin inhibitors has been found resulting in IC50 values as low as 0.048 mu M, a factor of ten more potent than Argatroban. Starting with non-chiral synthetic routes, a new stereospecific route was developed as well as a new solid-phase method. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00179-1
• 作为产物：
  描述：

  1-N-BOC-4-哌啶丙酸 在 palladium on activated charcoal lithium hydroxide 、 正丁基锂 、 2,4,6-三异丙基苯磺酰叠氮化物 、 氢气 、 双氧水 、 三甲基乙酰氯 、 双(三甲基硅烷基)氨基钾 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-1-boc-4-(2-cbz-氨基-2-甲氧基羰基乙基)哌啶
  参考文献：
  名称：

  Solution-phase and solid-phase synthesis of novel transition state inhibitors of coagulation enzymes incorporating a piperidinyl moiety

  摘要：

  2-Amino-3-piperidin-4-yl-propionic acid containing peptidomimetics are potent protease inhibitors when combined with an appropriate keto-thiazole or keto-carboxylic acid moiety. A novel P-1 residue in factor Xa and thrombin inhibitors has been found resulting in IC50 values as low as 0.048 mu M, a factor of ten more potent than Argatroban. Starting with non-chiral synthetic routes, a new stereospecific route was developed as well as a new solid-phase method. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00179-1

文献信息

• Compounds and Compositions as Channel Activating Protease Inhibitors
  申请人：Tully C. David

  公开号：US20070275906A1

  公开（公告）日：2007-11-29

  The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.

  该发明提供了化合物及其制药组合物，用于调节通道激活蛋白酶，并使用这些化合物来治疗、改善或预防与通道激活蛋白酶相关的疾病的方法，包括但不限于前列腺蛋白酶、PRSS22、TMPRSS11（例如TMPRSS11B、TMPRSS11E）、TMPRSS2、TMPRSS3、TMPRSS4（MTSP-2）、麦曲蛋白酶（MTSP-1）、CAP2、CAP3、胰蛋白酶、卡特普辛A或中性粒细胞弹性蛋白酶。
• [EN] CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR CGRP
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2017072721A1

  公开（公告）日：2017-05-04

  The disclosures herein relate to novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

  本公开涉及公式（I）中的新化合物，其中R1、R2、R3和R4如本文所定义，并且它们在治疗、预防、改善、控制或减少与CGRP受体功能相关的脑血管或血管疾病中的用途。
• CGRP receptor antagonists
  申请人：Heptares Therapeutics Limited

  公开号：US10300056B2

  公开（公告）日：2019-05-28

  The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

  本文所披露的内容涉及新型式化合物 其中 R1、R2、R3 和 R4 如本文所定义，以及它们在治疗、预防、改善、控制或减少与 CGRP 受体功能相关的脑血管或血管紊乱中的用途。
• Structure-Based Drug Discovery of <i>N</i>-((<i>R</i>)-3-(7-Methyl-1<i>H</i>-indazol-5-yl)-1-oxo-1-(((<i>S</i>)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-<i>d</i>][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine
  作者：Sarah J. Bucknell、Mark A. Ator、Alastair J. H. Brown、Jason Brown、Andrew D. Cansfield、Julie E. Cansfield、John A. Christopher、Miles Congreve、Gabriella Cseke、Francesca Deflorian、Christopher R. Jones、Jonathan S. Mason、M. Alistair O’Brien、Gregory R. Ott、Mark Pickworth、Stacey M. Southall

  DOI：10.1021/acs.jmedchem.0c01003

  日期：2020.7.23

  Structure-based drug design enabled the discovery of 8, HTL22562, a calcitonin gene-related peptide (CGRP) receptor antagonist. The structure of 8 complexed with the CGRP receptor was determined at a 1.6 angstrom resolution. Compound 8 is a highly potent, selective, metabolically stable, and soluble compound suitable for a range of administration routes that have the potential to provide rapid systemic exposures with resultant high levels of receptor coverage (e.g., subcutaneous). The low lipophilicity coupled with a low anticipated clinically efficacious plasma exposure for migraine also suggests a reduced potential for hepatotoxicity. These properties have led to 8 being selected as a clinical candidate for acute treatment of migraine.
• CGRP RECEPTOR ANTAGONISTS
  申请人：Heptares Therapeutics Limited

  公开号：EP3368525B1

  公开（公告）日：2019-03-13